Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032
Abstract
Previously our randomized phase III trial demonstrated that immunotherapy including dinutuximab, a chimeric anti-GD2 mAb, GM-CSF, and IL2 improved survival for children with high-risk neuroblastoma that had responded to induction and consolidation therapy. These results served as the basis for FDA approval of dinutuximab. We now present long-term follow-up results and evaluation of predictive biomarkers.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 27, 2021
- Source ID
- 10.1158/1078-0432.ccr-20-3909
Entities
People
- Alice L Yu
- Andrew L. Gilman
- Arlene Naranjo
- Ayse Batova
- Barry Shulkin
- Jacek Gan
- Jacquelyn A Hank
- John M. Maris
- Julie R. Park
- Katherine K. Matthay
- M. Fevzi Ozkaynak
- Malcolm A Smith
- Marguerite Parisi
- Mitchell B. Diccianni
- Paul M Sondel
- Rochelle Bagatell
- Sheena C. Tenney
- Susan L. Cohn
- Wendy B. London
Organizations
- Chang Gung University
- Harvard Medical School
- National Cancer Institute
- National Institutes of Health
- St. Baldrick's Foundation
- University of Florida
- University of Pennsylvania
- University of Washington